Supporting mass accumulation rate (MAR) as a predictive biomarker in multiple myeloma

In June 2018, LLS made an equity investment in Travera to support "Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma." Travera has developed a universal cancer biomarker with the potential of matching cancer patients to virtually any available cancer drug or combination of drugs. Travera uses a proprietary technology that was developed at MIT to measure the weight change (called mass response) of a patients’ cancer cells (tested outside the body) in response to a variety of cancer drugs. In the future, this mass response may enable oncologists to quickly determine which drugs to prescribe based on the actual responses of their patients’ tumor cells to candidate drugs, regardless of the mechanism of action. Travera is studying the use of its biomarker test in patients with relapsed and/or refractory multiple myeloma (RRMM) and are working with prominent academic institutions to enroll study participants.